Evaluation of Drug-Drug Interaction Between Henagliflozin and Hydrochlorothiazide in Healthy Chinese Volunteers

DOI: https://doi.org/10.2147/dddt.s433377

IF: 4.3188

2024-05-29

Drug Design Development and Therapy

Abstract:Qian Chen, 1, 2 Chengyin Yu, 1, 2 Qingqing Wu, 1, 2 Rong Song, 1, 2 Ye Liu, 1, 2 Sheng Feng, 3 Chen Yu, 1, 2 Jingying Jia 1, 2 1 Center Laboratory, Shanghai Xuhui Central Hospital, Shanghai, People's Republic of China; 2 Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, People's Republic of China; 3 Jiangsu Hengrui Pharmaceuticals Co., Ltd, Lianyungang, Jiangsu, People's Republic of China Correspondence: Jingying Jia, Center Laboratory, Shanghai Xuhui Central Hospital, No. 966, Huaihai Road (M), Shanghai, People's Republic of China, Tel/Fax +86-21-54030254, Email Purpose: Henagliflozin is an original, selective sodium-glucose cotransporter 2 (SGLT2) inhibitor. Hydrochlorothiazide (HCTZ) is a common anti-hypertensive drug. This study aimed to evaluate the potential interaction between henagliflozin and HCTZ. Methods: This was a single-arm, open-label, multi-dose, three-period study that was conducted in healthy Chinese volunteers. Twelve subjects were treated in three periods, period 1: 25 mg HCTZ for four days, period 2: 10 mg henagliflozin for four days and period 3: 25 mg HCTZ + 10 mg henagliflozin for four days. Blood samples and urine samples were collected before and up to 24 hours after drug administrations on day 4, day 10 and day 14. The plasma concentrations of henagliflozin and HCTZ were analyzed using LC-MS/MS. The urine samples were collected for pharmacodynamic glucose and electrolyte analyses. Tolerability was also evaluated. Results: The 90% CI of the ratio of geometric means (combination: monotherapy) for AUC τ,ss of henagliflozin and HCTZ was within the bioequivalence interval of 0.80– 1.25. For henagliflozin, co-administration increased C ss, max by 24.32% and the 90% CI of the GMR was (108.34%, 142.65%), and the 24-hour urine volume and glucose excretion decreased by 0.43% and 19.6%, respectively. For HCTZ, co-administration decreased C ss, max by 19.41% and the 90% CI of the GMR was (71.60%, 90.72%), and the 24-hour urine volume and urinary calcium, potassium, phosphorus, chloride, and sodium excretion decreased by 11.7%, 20.8%, 11.8%, 11.9%, 22.0% and 15.5%, respectively. All subjects (12/12) reported adverse events (AEs), but the majority of theses AEs were mild and no serious AEs were reported. Conclusion: Although C ss,max was affected by the combination of henagliflozin and HCTZ, there was no clinically meaningful safety interaction between them. Given these results, coadministration of HCTZ should not require any adaptation of henagliflozin dosing. Trial Registration: ClinicalTrials.gov NCT06083116. Keywords: henagliflozin, drug-drug interaction, hydrochlorothiazide, pharmacokinetics, tolerability, pharmacodynamics, selective sodium-glucose cotransporter 2 Over the past 20 years, the metabolic disease known as type 2 diabetes mellitus (T2DM), which is characterized by insulin resistance and hyperglycemia, has become an epidemic in both industrialized and developing nations. T2DM is a major global health concern. 1 Metformin, a thiazolidinedione insulin sensitizer, sulfonylurea insulin secretagogue, α-glycosidase inhibitors, and other medications with various modes of action are the primary anti-diabetic medications available. 2 Their drawbacks, however, include a limited ability to improve cardiovascular outcomes and, in certain cases, an increase in morbidity associated to cardiovascular disease. Certain medications, like rosiglitazone, pioglitazone, and saxagliptin, have been demonstrated to elevate the likelihood of hospitalization due to heart failure. 3,4 Furthermore, severe hypoglycemia may occur when certain oral hypoglycemic medications are used clinically. 5 A new class of medications called sodium-glucose cotransporter 2 (SGLT2) inhibitors is used to treat type 2 diabetes (T2DM). These medications work by preventing the kidneys from reabsorbing glucose, which allows more glucose to be excreted in the urine and lowers blood glucose levels. Clinical research has demonstrated that SGLT2 inhibitors, either taken by alone or in conjunction with other medications, have very potent hypoglycemia effects. 1,6,7 However, investigations on the effects on the kidneys and cardiovascular system have greatly broadened their application. Cardiorenal outcomes trials have proven to be effective in improving renal outcomes and lowering the risk of cardiovascular death, myocardial infarction, hospitalization for heart failure (HHF), and composite -Abstract Truncated-

pharmacology & pharmacy,chemistry, medicinal